Autism irritability drug study halted early
Symptom relief
Terminated
This study looked at the long-term safety of a drug called pimavanserin for treating irritability in children and teens (ages 5-17) with autism. It was an extension of an earlier 6-week study, lasting 52 weeks. The study was terminated early, and the main goal was to track side e…
Phase: PHASE2, PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated May 11, 2026 20:38 UTC